

Modulating Infant Immunity and Nutrition: The Emerging Role of Prebiotics, Probiotics, Postbiotics, HMO, Osteopontin in Human Milk and Formula Feeding in Infant Nutrition and Immunity Support

Said Eldeib^{1*}, Dinesh Banur¹, Ahmed Tahoun¹, Jayaraj Damodaran¹, Mohamed Chaudhary¹, Mohamed Othman Mohamed Eldesoky², Mohamed Elmesserey³, Rafia Owera⁴, Hadi Haddad⁵, Julia Bilal Aga⁶ and Zainab Saeed Khan⁷

¹Department of paediatrics, ADSCC/ YAS clinic Hospital, AD, UAE

²Department of paediatrics Specialized Rehabilitation Hospital, AD, UAE

³Department of paediatrics, Al Jalila Children's Hospital, Dubai UAE

⁴Department of paediatrics, Prime medical centre Jumeirah, Dubai, UAE

⁵Department of paediatrics, Lebanese American University mc, Lebanon

⁶Department of paediatrics, University hospital Sharjah, UAE

⁷Department of paediatrics, Chelsea and Westminster hospital, UK

*Corresponding author: Dr. Said Eldeib, Department of paediatrics ADSCC/ YAS clinic Hospital, Abu Dhabi, UAE

Received: July 15, 2025

Published: November 25, 2025

Abstract

Background and Aims

Numerous studies have demonstrated that intestinal microbiota under the influence of diet shapes the maturation of the immune system, A new challenge for dairy industries is to develop formulas inducing the maturation of immunity and the microbiota that can be observed in breastfed delivered vaginally, representing reference infants., in this abstract we will focus on pre, pro post biotics and Oste pontin role in modulating infant gut immunity.

To establish the current knowledge on biotics” in infant milk, Articles mainly published over the last 12 years, were evaluated based on their title and abstract, checking for the inclusion and exclusion criteria. focused only on primary and secondary outcomes at a nonclinical level regarding the microbiota, digestive metabolites, and intestinal immunity.

Clinical beneficial effects of prebiotics (mainly GOSs, FOSs, and HMOs) have been observed, particularly, to effect a modest reduction in infections in infants, Some bacteria (probiotics)can modulate the whole microbiota composition and digestive microenvironment postbiotics is metabolites impacts on the bacterial microbiota are increasingly observed, the mechanisms and the long-term positive or negative consequences on microbiota function, immunity, and the metabolomic profiles of these pre-, pro-, syn-, and postbiotics given early in life when the microbiota and the immune system are still immature Oste pontin (OPN), a multifunctional protein, is present abundantly in human milk, but not in bovine milk and infant formulas. A recent RCT showed that supplementing infant formula with bovine milk OPN (bOPN) resulted in better immune outcomes. Prebiotics, probiotics, postbiotics, HMO, Osteopontin have emerging role in modulating infant immunity through nutrition.

Keywords: Prebiotics; Probiotics; Postbiotics; HMO Osteopontin in Human Milk

Introduction

A host and its commensal microbiota live in symbiosis, allowing both the establishment of local immunity and maturation of the intestinal epithelium [1,2]. The development of the intestinal microbiota at birth is progressive and sequential. The microbiota matures during the first years of life until reaching

a kind of “status-quo” after 3 years. The main characteristic of the primo-colonizing pattern at birth is high inter-individual variability, reflecting the fragile acquisition of a diverse ecosystem. Colonization becomes massive after birth [3]. It starts with Enterobacteriaceae, then Bifidobacterium, Bacteroides, and Clostridium [3,4]. Depending on the type of birth, the early

microbiota of infants differs, with a gut microbiota close to the mother's vaginal microbiota in the case of vaginal delivery and one close to the mother's skin microbiota for cesarean births [3,5]. Infants born via C-section have more *Clostridium* and pathogenic potential bacteria and less *Bifidobacteria* and *Bacteroides* [4]. Significant variations in the microbiota due to the type of birth disappear between 6 and 14 months [6]. Breast-feeding remains the strongest factor influencing the digestive microbiota of infants in the first year of life [6]. *Bifidobacteria* usually represent the dominant taxon (up to 90%) in breastfed infants delivered vaginally [4]. Breastfeeding provides *Bifidobacterium* sp., *Lactobacillus* sp., and *Staphylococcus* sp. naturally present in mothers' milk. More importantly, breastfeeding promotes the implantation of *Bifidobacteria* thanks to the richness and high diversity of Human Milk Oligosaccharides (HMOs), which are uniquely metabolized by the bacteria. In a virtuous circle, endogenous synthesis of secretory IgA (sIgA) by the intestinal mucosal lymphocytes into the lumen is also conditioned by the presence of microbiota, particularly *Bifidobacteria* [7], after the first weeks of life when sIgA can only be provided by breastmilk. sIgA is an important weapon in immune defense against pathogens and toxins [2]. Conversely, formula-fed infants have a faster maturation of their gut microbiota compared to breastfed infants. Indeed, microbiota from formula-fed infants is diversified earlier, resulting in an enrichment in anaerobic bacteria, such as *Bacteroides* and *Clostridium*, with a lower representation of so-called "beneficial" bacteria, such as *Bifidobacteria* and *Lactobacilli* [8]. Overall, a lower abundance of *Bifidobacteria*, as observed in cesarean-born or formula-fed infants, is a risk factor for impaired metabolism of Short-Chain Fatty Acids (SCFAs), an increase in stool pH, and a weakening of the intestinal barrier function. As a result, the dialogue between the microbiota and the host is disturbed, the risk of colonization by pathogens is greater, and digestive inflammation can be observed. All these parameters may also participate in altered immune system programming and metabolic disorders. These infants have an increased risk of developing immune-related disease, such as allergic diseases, autoimmune diseases, or other chronic digestive or extradi- gestive diseases [4,5].

For several reasons, some newborns and infants cannot benefit from breastfeeding. The objective of dairy industries is then to ensure that infant formulas are as close as possible to breastmilk, both in its composition and its physiological properties. Some breastmilk bioactive components are unique and specific to human milk, and some, such as cytokines and growth factors, are associated with health outcomes in infancy (e.g., food allergies [9]). However, their addition to infant formula is not planned to date (due to cost and stability). On the other hand, supplementation with prebiotics or health-promoting (live) bacteria seems a more rational and easier approach to improve the health-promoting capacity of formulas. Since breastfed infants have more *Bifidobacterium* in their microbiota, the first strategy was to add probiotics and, in particular, *Bifidobacteria* directly into infant formulas, followed by prebiotics and, more recently, synbiotics and postbiotics for their bifidogenic effects, as well as for their own positive expected effects on immunity. Nowadays, more than half of formula-fed infants consume probiotic-enriched formula in France [10]. The goal of this review is to sum up the pre-, pro-, syn-, and postbiotics (named "-biotics" in this review) used in infant formulas and the expected and proven clinical benefits for infants regarding microbiota composition, immunity, and allergies.

Definitions

Probiotic: An oral supplement or a food product that contains a sufficient number of viable microorganisms to alter the microflora of the host and has the potential for beneficial health effects [11].

Prebiotic: A nondigestible food ingredient that benefits the host by selectively stimulating the favourable growth and/or activity of 1 or more indigenous probiotic bacteria [12].

Synbiotic: A product that contains both probiotics and prebiotics. Evidence for synergy of a specific prebiotic for a probiotic in the product is not essential. Synbiotics may be separate supplements or may exist in functional foods as food additives [11,12].

Postbiotic: A metabolic by product generated by a probiotic microorganism that influences the host's biological functions [13,14]. **Functional food:** Any modified food or food ingredient that provides a health benefit beyond that ascribed to any specific nutrient/nutrients it contains. It must remain a food, and it must demonstrate its effect in amounts normally expected to be consumed in the diet. Benefits may include functions relevant to improving health and well-being and/or reduction of risk of disease. Any food that contains probiotics or prebiotics is a functional food. An example of a functional food is live culture yogurt that contains probiotic bacteria, prebiotics, and other dietary nutrients. Human milk may also be considered a functional food; it contains substantial amounts of oligosaccharides (prebiotics) and may contain some naturally occurring probiotic bacteria (103 of *bifidobacteria* per mL of expressed human milk [17]).

What are Probiotics?

Probiotic microorganisms are typically members of the genera *Lactobacillus*, *Bifidobacterium*, and *Streptococcus* [11,12]. These bacteria are formative, obligatory, or facultative anaerobic organisms, which are typically nonmotile and of varying shapes. They typically produce lactic acid. Their inherent biological features enable them to predominate and prevail over potential pathogenic microorganisms in the human digestive tract. It is currently hypothesized that these microbes generate small molecular metabolic by products that exert beneficial regulatory influence on host biological functions, including short-chain fatty acids such as butyrate. These metabolic by products are sometimes referred to as "postbiotics" and may function biologically as immune modulators [13,14].

The most studied probiotic bacteria to date include *Lactobacillus rhamnosus* GG (LGG), *Bifidobacterium lactis*, and *Streptococcus thermophilus*. These probiotic bacteria are biologically different from the Gram-negative, motile, non-lactic-acid-producing bacteria such as *Klebsiella*, *Pseudomonas*, *Serratia*, and *Proteus* species, which also may be prominent flora in the human digestive system. These potentially harmful bacteria may translocate across the intestinal epithelium and could result in disease in humans [18,19]. Some yeasts and yeast byproducts have also been studied and have been frequently used as probiotic agents, such as the yeast *Saccharomyces boulardii*. Probiotic bacteria can be delivered and ingested separately as medicinals or supplements. They can also be mixed with, added to, or naturally exist in functional foods.

What are Prebiotics?

Prebiotics are usually in the form of oligosaccharides, which may occur naturally but can also be added as dietary supple-

Citation: Said Eldeib* Dinesh Banur, Ahmed Tahoun, Jayaraj Damodaran, Mohamed Chaudhary, Mohamed Othman Mohamed Eldesoky, Mohamed Elmesserey, Rafia Owera, Hadi Haddad, Julia Bilal Aga and Zainab Saeed Khan. Modulating Infant Immunity and Nutrition: The Emerging Role of Prebiotics, Probiotics, Postbiotics, HMO, Osteopontin in Human Milk and Formula Feeding in Infant Nutrition and Immunity Support. *IJCMCR*. 2025; 56(4): 003

DOI: 10.46998/IJCMCR.2025.56.001393

ments to foods, beverages, and infant formula [14]. Although indigestible by humans, their presence in the digestive system selectively enhances proliferation of certain probiotic bacteria in the colon, especially Bifidobacterial species. Prebiotic oligosaccharides often contain fructose chains with a terminal glucose and typically consist of 10 or fewer sugar molecules. Examples of prebiotic oligosaccharides include Fructo-Oligosaccharides (FOSs), inulin, Galacto-Oligosaccharides (GOSs), and soybean oligosaccharides. Inulin is a composite oligosaccharide that contains several FOS molecules. The complex polysaccharides that constitute dietary fiber can also be considered to be prebiotic agents. Although dietary nucleotides do not fit the exact definition of a prebiotic, they are prebiotic-like agents and have immunomodulating and direct intestinal biological properties [19]. Some infant formulas contain a limited amount of added free nucleotides (7–20 mg/dL) [19]. Human milk, on the other hand, contains a substantial but variable number of oligosaccharides (14 g/L) as well as free nucleotides (up to 20% of nonprotein nitrogen) [20]. Some infant-formula manufacturers now add prebiotic oligosaccharides to their products. Beverages and nutritional supplements marketed for older infants, children, and adults contain oligosaccharides and nucleotide additives in varying amounts.

Intestinal Bacterial Colonization and Development of the Intestinal Mucosal Defence System

Similar to the fetus, an infant at the time of birth has a sterile gastrointestinal tract, but bacterial colonization occurs rapidly [21-23]. The new born infant's gestational age, mode of delivery, and diet seem to have significant effects on this process. Neonates who are born by Caesarian delivery, born preterm, and/or exposed to perinatal or postnatal antibiotics have a delay in intestinal commensal probiotic bacterial colonization. When delivered vaginally, breastfed infants and formula-fed infants have a similar pattern of bacterial colonization at 48 hours of age. However, by 7 days of age, approximately two-thirds of formula-fed infants have a predominance of *Bacteroides fragilis*, compared with only 22% of breastfed infants [21]. Toward the end of the first month of life in developing countries, breastfed infants are found to have Bifidobacteria-predominant colonization, whereas formula-fed infants have equal colonization with *Bacteroides* and Bifidobacteria species. In resource-rich countries, however, differences are less pronounced between breastfed and formula-fed infants. The composition of intestinal microflora does not change significantly after infancy. Therefore, the composition of fecal flora in older children and adults is less variable and not as dependent on diet. In fact, beyond infancy, bacterial concentrations in the colon are typically 10¹² colony-forming units per mL of intestinal contents (10-fold the total number of human cells in the human body), and anaerobic bacteria far outnumber aerobic coliforms [24]. Typically, 500 different bacterial species contribute to an adult's colonic microflora, but 99% of the microflora are accounted for by 30 to 40 species [24]. The descriptive terms of "microbiota" and "microbiome" are newer terms that are replacing such terms as "microflora" in an attempt by researchers in the field to better define one's microbial environment [25]. "Microbiota" refers to a population of microscopic organisms that inhabit a bodily organ or portion of a person's body, and human "microbiome" refers to the unique entire population of microorganisms and their complete genetic elements that inhabit one's body. The intestinal mucosal defense system is an integral part of a sophisticated immunoregulatory network that includes the intestinal microflora [22-25]. Recognition of

self- and non-self-antigens begin early in life, perhaps even in utero, and is significantly influenced by events that occur within the digestive system soon after birth. The immunoresponsiveness of the digestive system is significantly affected by the young infant's diet, state of bacterial colonization, and early exposure to potential infectious pathogens and antibiotics as well as the infant's genotype. It is thought that the occurrence of many diseases, both intestinal and nonintestinal, can be related to dysregulation or interference with the early development of the intestinal mucosal defense system [26,27]. Examples of these diseases include those thought to be atopic (asthma, eczema, and allergic rhinitis) or autoimmune (multiple sclerosis, type 1 diabetes mellitus, and chronic inflammatory bowel disease [IBD]) [26]. Certainly, the overriding determining factor in development of the immune system is one's genetic predisposition [23]. The molecular basis for innate and acquired immunity is thought to reside in the recognition and response of mature T lymphocytes to trigger molecules, such as those derived from dietary and bacterial-breakdown products within the intestinal tract [27]. Trigger molecules also include dietary nucleotides and oligosaccharides. Toll-like receptors located in the surface membrane of T lymphocytes facilitate recognition of these trigger molecules, which eventually leads to specialized T lymphocyte recognition and response to subsequent exposure to the same or very similar molecules. Thus, T-lymphocyte recognition of specific oligosaccharides bound to intestinal pathogens plays an important role in preventing gastrointestinal illness. Given these important influences on intestinal microflora colonization and immune function, the infant's early diet and intestinal microbial environment are thought to serve as pivotal factors in overall health. Probiotic bacteria, postbiotic bacterial byproducts, and dietary prebiotics are believed to exert positive effects on the development of the mucosal immune system. It is also believed that exposure to "nonbeneficial" microorganisms and antimicrobial agents in the newborn period may result in immune dysregulation in susceptible individuals and may lead to some chronic disease states. There is evidence that human milk contains mononuclear cells that traffic intestinally derived bacterial components from the mother to her infant. The ingested human milk containing the bacterial components derived from the mother are thought to influence her young infant's developing immune system. This process is termed "bacterial imprinting," and its overall biological effect requires further study [28]. Prebiotics Definition Prebiotics are indigestible substrates for humans but are metabolized by host microorganisms and exert a beneficial effect on health [28,29]. They can selectively stimulate the growth or activity of specific bacteria and, thus, promote the production of SCFAs, which have pleiotropic effects both locally, i.e., in the intestinal tract, and at distance on other tissues [29,30]. European regulations do not allow the mention of prebiotics on food packaging and the related health claim without an established and proven effect by clinical studies. In the USA, prebiotics have no legal definition from the FDA (Food and Drug Administration). Prebiotics are naturally present in many fiber-rich foods. The most common prebiotics are carbohydrate-based, such as resistant starch, cellulose, pectin, and fructan, as well as oligosaccharides structured in Fructo-Oligosaccharides (FOSs) and Galacto-Oligosaccharides (GOSs). Breastmilk also contains a large number of natural prebiotics, i.e., Human Milk Oligosaccharides (HMOs). Dietary fibers have numerous demonstrated direct and indirect health benefits through the fiber-microbiota-immune relationship. The main bacterial metabolites coming from the fermentation of fibers

are SCFAs (mostly acetate, butyrate, and propionate), which are potent immunomodulators associated notably with allergy protection [31]. Prebiotics added in adequate levels to infant formula are well-tolerated and ensure normal growth [32]. Adverse events can be observed at high levels of consumption.

HMOs

HMOs are the third most prevalent component of human milk, after lactose and lipids (33). They are indigestible carbohydrates that selectively stimulate the colonic growth of HMO-consuming bacteria, including Bifidobacteria [35,36]. More than 200 different HMOs have been identified in human milk, with up to 130 for an individual mother. HMO composition is highly influenced by the genetic status of the mother, i.e., secretor and Lewis's statuses determining the expressions of FUT2 and FUT3 fructosyltransferases, respectively. As a result of FUT2 activity, 2'-fucosyllactose (2'FL) is the most abundant HMO in breastmilk from secretor mothers (70–90% depending on country), representing 20–40% of the total HMO concentration in colostrum [36]. HMOs promote intestinal barrier function, prevent adhesion of pathogens to epithelial cells, act as decoy receptors, and stimulate the development of an infant's immune system either directly or through a microbiota-mediated effect [37]. Globally, HMOs may then help in preventing infections and diseases related to immune dysregulation, such as allergic and autoimmune diseases [35,37]. It is still unclear whether the protective effect of HMOs is specific to certain classes of HMOs [45] or if it relies on their high diversity and synergic actions. To date, due to technical difficulties and cost issues, only a few HMOs have been synthesized, i.e., 2'FL, 3-Fucosyllactose (3FL), 3'-Sialyllactose (3'SL), 6'-Sialyllactose (6'SL), and Lacto-N-neotetraose (LNnT), for use as supplements in infant formulas. In vitro studies evidenced that 2'FL increased the relative proportions of Bifidobacterium adolescentis and other bacteria that produce butyrate, a beneficial SCFA [47]. 2'FL also reduced the adhesion of pathogens such as Clostridium difficile, Campylobacter jejuni, enteropathogenic E. coli, and Pseudomonas aeruginosa to epithelial cells [37]. In infants, supplementation with 2'FL promoted the growth of Bifidobacterium species and limited the colonization of opportunistic pathogens, such as C. difficile and K. pneumonia [36]. Feeding with a formula supplemented with 2'FL and GOS (2.4 g total oligosaccharides/L: 2'FL at 0.2 g/L with GOS at 2.2 g/L (n = 54) or 2'FL at 1 g/L with GOS at 1.4 g/L (n = 48)) for 6 weeks resulted in inflammatory cytokine profiles in the plasma that were intermediate between that of infants fed with control infant formula (GOS only, 2.4 g/L, n = 48) and that of exclusively breastfed infants (n = 51) [38]. In healthy infants, the use of infant formulas enriched with 2'FL (1 g/L) and LNnT (0.5 g/L) (n = 88, vs. n = 87 in the control group) during the first 6 months of life was associated with a decrease in lower respiratory infections and with the use of antibiotics and antipyretics before the age of 1 year, but these results were the secondary endpoints of a tolerance study [39]. At 3 months, fecal microbiota compositions (alpha diversity; beta diversity; relative abundance of Bifidobacterium, Escherichia, unclassified Peptostreptococcaceae, and Streptococcus) of infants supplemented with HMOs were closer to that of breastfed children than that of the control group. HMOs increased the proportion of infants with a fecal community type characterized by high abundance of Bifidobacteriaceae compared to the control group. The formula-fed group with the higher abundance of Bifidobacteriaceae required less frequent antibiotics during the first year than infants with other fecal community

types. These results suggested that the anti-infectious effect of HMOs is linked to the composition of the microbiota [40]. In another trial, infants were fed from 14 days to 4 months of age with an experimental formula with a five-HMO mix (2'FL at 2.99 g/L, LNnT at 1.5 g/L, 3FL at 0.75 g/L, 6'SL at 0.28 g/L, and 3'SL at 0.23 g/L) (n = 103) or a control formula (n = 104). In the safety outcomes, no differences were shown regarding infections and infestations [41]. Another randomized study with a similar formula (2'FL at 3 g/L, LNnT at 1.5 g/L, 3FL at 0.8 g/L, 6'SL at 0.3 g/L, and 3'SL at 0.2 g/L) showed that the experimental-formula-fed infants (n = 130) had less recourse to healthcare professionals for illness than the control group (n = 129) before 3 months of age (secondary outcomes) [42]. From 1 to 2.5 years of age (n = 461), the incidence of upper respiratory tract infections was similar between randomized infants receiving four different young-child formulas containing GOS (4 g/L), TGF- β (9.9 or 15 μ g/L), lactoferrin (0 to 1.7 g/L), immunoglobulins (0 to 1 g/L), milk fat (0.5 to 17 g/L), and 2'FL (0 or 3 g/L). However, according to the secondary outcomes of the study, children supplemented with 2'FL had longer durations of upper respiratory tract infections and more episodes of coughs and runny noses than the group with the similar formula without 2'FL (p < 0.05 and p < 0.01, respectively). Fever episodes were less frequent, but gastrointestinal tract infections occurred more often in the group supplemented with 2'FL, immunoglobulins, and lactoferrin than in the group fed with formula without these components (p < 0.01 each) [43].

Whey-based extensive hydrolyzates with added HMOs (2'FL at 1 g/L and LNnT at 0.5 g/L) are free of residual milk proteins and were well-tolerated by infants allergic to cow's milk [45]. Cow's-milk-allergic infants in the HMO group (n = 94) and in the control group (n = 96, same formula without HMOs) had similar incidences of upper and lower respiratory tract infections, gastrointestinal infections, other viral infections, and urinary tract infections between enrollment (from 0 to 6 months) and 1 year of age. In a subanalysis, the authors evidenced a significant reduction in the frequency of upper respiratory tracts infections compared to the control group (hazard ratio: 0.58; 95% CI: [0.41–0.83]). There was a slight reduction in the occurrence of otitis media during the follow up in the HMO group. The overall uses of antibiotics and antipyretics were similar in both groups, but between the visits at 4 months for follow-up and 12 months of age, infants in the HMO group required fewer antipyretics (p = 0.02) [44]. There are currently no published clinical studies evidencing acceleration of the acquisition of tolerance to cow's milk [44].

To summarize, results about the prevention of infections through HMO supplementation of infant formula are divergent, and the potential benefits of such interventions should be further studied. GOSs Galacto-Oligosaccharides (GOSs) are prebiotics that are more easily synthesized than HMOs, explaining why they are more frequently used in infant formulas. In vitro, they limit the adhesion of pathogens to epithelial cells and stimulate the Treg (IL10) and Th1 (increase in IFN- γ and decrease in TNF- α) pathways, inducing anti-inflammatory and regulatory effects [55]. In animals, GOSs promoted an increase in SCFAs and stimulated intestinal barrier function [56]. In infants, GOS supplementation (4.4 to 5 g/L) (n = 44, vs. n = 37 in the control group without GOS) decreased fecal pH and butyric acid concentration, whereas the effect on fecal sIgA was limited [45]. They also had bifidogenic effects [47,55,56] and re-

duced the gastrointestinal colonization of *Clostridium* ($n = 83$ fed with the study formula vs. $n = 79$ in the control group) [46]. Bozensky et al. studied the effect of GOS supplementation (5 g/L) in a partially hydrolyzed formula on atopic dermatitis in infants with a family history of atopy and moderate eczema at recruitment ($n = 52$ in the intervention group vs. $n = 51$ in the control group). Supplementation was provided from 6 weeks to 6 months. The SCORAD index decreased in both groups (supplemented or not), with no significant differences between the groups [47]. GOSs associated with polydextrose (PDX) (total of 4 g/L; 1:1 ratio) also had a bifidogenic effect ($n = 91$ PDX/GOS group; $n = 91$ control group; $n = 83$ breastfed group) [58] and was evidenced in increased counts of *Lactobacilli*, particularly in *L. rhamnosus*, in supplemented infants ($n = 77$), thus showing a gut microbiota closer to that of breastfed infants ($n = 71$) than to non-supplemented infants ($n = 80$) [48]. In young infants at risk of atopy, GOS/PDX supplementation (total of 4 g/L; 1:1 ratio) ($n = 201$) prevented respiratory infections in the first two years of life, with a rate similar to that observed in breastfed infants ($n = 140$) [49]. In this study, supplementation induced differences in fecal microbiota at 9–12 months of life, with increases in *Bifidobacteria* and *Clostridium* cluster I. The supplementation did not prevent atopic dermatitis, but the increased load of fecal *Bifidobacteria* at 9–12 months was associated with protection against respiratory infection. Atopic-dermatitis-free infants had higher colonization with *Clostridium* postintervention [50]. FOSs Fructo-oligosaccharides (FOSs) derived from inulin are also known to be bifidogenic [61–63], despite controversies [51]. In vitro, FOSs limit the adhesion of pathogens to intestinal cells, strengthen the intestinal barrier, and stimulate the Th1 immune pathway, as observed for GOSs [52]. Gut inflammation monitored with fecal calprotectin was not affected after 8 weeks of supplementation (3 g/L) ($n = 10$ –12 infants per group; prebiotic formula, control formula, and human milk) [61] or after 12 months of supplementation (short- and long-chain FOS and inulin combination, total of 8 g/L) ($n = 14$ fecal samples in prebiotic group and $n = 11$ in the control group) [63]. Conversely, FOSs have induced increased intestinal production of sIgA [53–55].

GOSs/FOSs at a Ratio of 9:1

Fifteen years ago, one of the first originator studies in infants fed with a formula with GOSs/FOSs (6 g/L; GOS/FOS ratio: 9/1) ($n = 19$) showed a trend of increased rate of fecal sIgA compared to a standard formula ($n = 19$) [56]. After 1 year of intervention (4 g/L), Bruzzese et al. highlighted a reduction in digestive infections during the study period. There was a decreased number of episodes (0.12 episode per child per year vs. 0.29, $p = 0.015$), with fewer children having at least one episode of acute infectious gastroenteritis (10.4% vs. 23.9%, $p = 0.01$) and fewer children having at least two courses of antibiotics (40.0% vs. 66.2%, $p = 0.02$) ($n = 96$ in the prebiotic group; $n = 105$ in the standard formula group). Moreover, supplementation was associated with a non-significant decrease in the number of children who had at least three episodes of upper respiratory infections (28.3% vs. 44.6%, $p = 0.06$) [58]. When supplementation with GOSs/FOSs (9:1) was pursued up to 12 months of age, Shahramian et al. observed an infectious history similar to breastfed infants. The total duration of diarrhea was shorter in supplemented-formula-fed infants compared to non-supplemented (4.4 vs. 12.3 days, $p < 0.001$) and similar to that observed in breastfed infants (4.4 vs. 6.8) ($n = 60$ in each group). Additionally, GOS/FOS-supplemented infants had fewer occurrences of fever episodes and respiratory tract

infections compared to regular-formula-fed infants but the same as that of breastfed infants [59]. The European Multi-centric Infection Prevention Study (MIPS) demonstrated that a formula with a specific mixture of shortchain GOSs (scGOSs) plus long-chain FOSs (lcFOSs) (6.8 g/L, ratio 9:1) and pectin-derived acidic oligosaccharides (1.2 g/L) decreased the rate of atopic dermatitis by 44% in infants not considered to be at risk in their first year of life. This significant effect was not sustained at preschool age after oligosaccharide supplementation was stopped ($n = 172$ in the probiotic group) [60,61]. Holscher et al. studied the effect of a partially hydrolyzed whey formula supplemented with GOSs and FOSs (4 g/L, 9:1) on intestinal microbiota composition. After 6 weeks of GOS/FOS supplementation ($n = 36$), the absolute and relative quantities of *Bifidobacteria* were similar to those observed in breastfed infants ($n = 33$) and higher than those in non-supplemented infants ($n = 33$). The SCFAs (mainly acetate, propionate, and butyrate) were higher in the supplemented group than in the breastfed group. As a result, fecal pH was more acid in prebiotic and breastfed groups [62]. Another partially hydrolyzed whey protein infant formula containing scGOSs, lcFOSs (6.8 g/L; GOS/FOS ratio: 9:1), and pectin-derived acidic oligosaccharides (1.2 g/L) ($n = 57$) showed similar results in terms of bacterial taxonomic and metabolite compositions of gut microbiota close to those of breastfed infants ($n = 30$) [63,64]. However, this formula failed to prevent eczema by 12 and 18 months in high-risk infants ($n = 341$) compared to a standard cow's milk formula [$n = 360$] [65,66]. Several randomized controlled double-blind studies have focused on the use of a combination of GOSs/FOSs (8 g/L; GOS/FOS ratio = 9:1) added to an extensive whey hydrolyzate formula provided during the first 6 months of life. The aim of this formula was to prevent atopic disease in at-risk infants (at least one of the two parents having atopy). At 6 months, the cumulative incidence of atopic dermatitis was lower in the supplemented group (9.8% vs. 23.1%, $p = 0.014$, total $n = 206$) [71]. In a subgroup of 84 children, the supplemented infants had significantly lower totals of IgE, IgG1, IgG2, and IgG3 antibody concentrations in serum than non-supplemented infants [72]. A gut microbiota analysis revealed an increase in the number of *Bifidobacteria* at 6 months under GOS/FOS supplementation (subgroup of 98 children) [71]. At 2 years of age ($n = 134$), a significant reduction in the cumulative incidence of allergic manifestations was observed (atopic dermatitis: 13.6% vs. 27.9%; recurrent wheezing: 7.6% vs. 20.6%; urticaria: 1.5% vs. 10.3%) [73]. Supplemented infants also had fewer episodes of upper respiratory infections and fevers and fewer courses of antibiotics [67,68]. At 5 years ($n = 92$), i.e., 4.5 years after stopping the prebiotics, a lower cumulative incidence of allergic manifestations was still observed in the supplemented group (30.9% vs. 66.0%, $p < 0.01$), with notably less atopic dermatitis [69].

GOSs and/or FOSs

After 4 months of supplementation with GOSs (0.6 g/100 g), FOSs (0.8 g/100 g), and 1,3-olein-2-palmitin (OPO) (4 g/100 g), the most abundant triacylglycerol in breastmilk, ($n = 22$ in the supplemented formula group), the alpha diversity and richness of gut microbiota decreased compared to infants fed with regular formula ($n = 13$), approximating that of breastfed children ($n = 48$). GOS/FOS/OPO supplementation was associated with a beta diversity (meaning the phylogenetic distance between samples) closer to that of breastfed infants, with a higher relative abundance of *Enhydrobacter* and *Akkermansia* [70]. In terms of microbiota metabolism functions, supple-

mented children and breastfed children had similar proportions of intestinal bacteria related to septicemia and ureolysis [71]. In an ELFE cohort, no association was observed between the consumption of GOSs/FOSs or GOSs only at 2 months and the occurrence of respiratory disease up to 5.5 years. Nevertheless, early use of GOSs was associated with a lower risk of upper respiratory tract infections compared to infants never supplemented with GOSs (OR: 0.87; 95% CI:

Synbiotic

Definition A synbiotic is a “mixture comprising live microorganisms and substrate(s) selectively utilized by host microorganisms that confers a health benefit on the host” [73]. The synergistic and the complementary effects of the substrate, which is not necessarily a prebiotic, make it possible to gain the effects of the probiotic and the substrate as a nonstimulant on the microbiota and immune functions. Yogurt is the archetype symbiotic food in lactose intolerance, with a health claim recognized by the EFSA. Postbiotics Definition Postbiotics are a “preparation of inanimate microorganisms and/or their components that confers a health benefit on the host”. They are “deliberately inactivated microbial cells with or without metabolites or cell components that contribute to demonstrated health benefits” [74,75]. Postbiotics Produced by *Lactobacillus paracasei* (CBA L74): Several Italian teams have taken an interest in postbiotics resulting from the fermentation of skimmed milk with *Lactobacillus paracasei* (CBA L74), a strain isolated from the feces of healthy infants [76,77]. In brief, the fermented milk was prepared from skimmed milk fermented with 106 CFU of *L. paracasei* CBA L74/g. The bacterial growth was stopped after 15 h of incubation at 37 °C when the bacteria reached 5.9×10^9 CFU/g, and the bacteria was inactivated with a quick heating. An initial study in mice showed a protective effect of milk fermented using *Lactobacillus paracasei* (CBA L74) in induced colitis, protection against pathogens (*Salmonella*), and inhibition of pro-inflammatory cytokines in favor of anti-inflammatory cytokines [78]. The active components were the metabolites from the fermentation and not the live or killed bacteria [78]. Then, thanks to a skim cow's milk fermented with *L. paracasei* L74 (not infant formula), the authors reported fewer common infections (in particular, acute gastroenteritis, pharyngitis, laryngitis, and tracheitis) and less use of drugs (antipyretics, antibiotics, and corticosteroids) in children from 12 to 48 months of age supplemented over a period of 3 months. Immuno-stimulation has been demonstrated, with increases in concentrations of fecal peptides and proteins (α -defensin, β -defensin, sIgA, and cathelicidin LL-37) resulting from the activation of the innate and acquired immune system [78]. Finally, this principle of fermentation (fermented spray-dried milk for infant milk tins) was applied to an infant formula administered to newborns up to 3 months of age (three groups: intervention, control, and breastfed; n = 26 in each group) [78]. Infants receiving the fermented formula had a similar microbiota to that of breastfed infants, namely a reduction in fecal bacterial diversity, an intermediate level of sIgA, and a metabolomic profile close to that of breastfed infants. However, over the period studied, unlike the studies by Corsello et al. [79] and Nocerino et al. [79], no difference in antimicrobial peptides was observed [80].

Postbiotics Produced by *Bifidobacterium breve* C50 and *Streptococcus thermophilus* ST065: *Bifidobacterium breve* C50 and *Streptococcus thermophilus* ST065 are lactic-acid-producing bacteria with anti-inflammatory properties on intestinal cells

in vitro [80]. A fermented infant formula based on these two strains with no living bacteria in the final product was tested in healthy infants (n = 464) and compared to infants receiving non-supplemented formula (n = 449). Fermented and control formula were provided for 5 months after the age of 4 months. While the incidence of acute diarrhea was the same in both groups, the severity of acute gastroenteritis was less in the fermented milk group, with fewer hospitalizations, fewer cases of acute dehydration, fewer medical consultations, and fewer prescriptions for oral rehydration solutions [81]. Between 6 and 24 months of age, the incidence of cow's milk protein allergy was the same in both groups (n = 66 and 63 in the fermented milk group and standard formula group, respectively), but sensitization to milk assessed by skin prick tests and digestive or respiratory symptoms of suspected allergy were lower in infants at high risk of atopy receiving the postbiotic-supplemented formula [82]. The fecal pH was similar from day 3 of life to 4 months in newborns for infants fed the fermented milk (n = 30) and breastfed (n = 30) and was more acidic than in infants fed the standard formula (n = 30) [83]. When this fermented formula (containing 0.25 g of 3'-galactosyllactose/L) was combined with GOSs/FOSs (8 g/L, ratio of 9:1) (n = 30), fecal sIgA concentrations and the compositions of the fecal microbiota were similar to those of breastfed infants (n = 30) [84,85]. Nevertheless, untargeted metabolomic profiles remained distinct, even if stable over time, between infants fed with pre- and postbiotic-supplemented formula and breastfed infants, with 261 different metabolites at the end of the study (vs. 404 different metabolites between the control formula and the breastfed group) [86].

Postbiotics produced by *Bifidobacterium animalis* sp. lactis CECT 8145 BPL1TM: According to secondary outcomes of the INNOVA 2020 study, infants randomized to be fed with an intervention formula (containing a thermally inactivated postbiotic, BPL1TM, and a lower amount of protein, a lower casein-to-whey protein ratio, and a double amount of docosahexaenoic acid/arachidonic acid compared to a standard formula) (n = 70) exhibited less atopic dermatitis and fewer bronchitis and bronchiolitis episodes than infants in the standard group (n = 70) (p = 0.03). These rates were similar as in breastfed children (n = 70) (p = 1.0). Other morbidities, such as infections, were not different among the three groups during the timeframe of the study

Atopic Diseases

Prevention of Atopic Disease As previously mentioned, the sequence of bacterial intestinal colonization of neonates and young infants is probably important in the development of the immune response [87]. Recognition by the immune system of self and nonself, as well as the type of inflammatory responses generated later in life, are likely affected by the infant's diet and acquisition of the commensal intestinal bacterial population superimposed on genetic predisposition. During pregnancy, the cytokine inflammatory response profile of the fetus is diverted away from cell-mediated immunity (T-helper 1 [Th1] type) toward humoral immunity (Th2 type). Hence, the Th2 type typically is the general immune response in early infancy. The risk of allergic disease could well be the result of a lack or delay in the eventual shift of the predominant Th2 type of response to more of a balance between Th1- and Th2-type responses [88]. Administration of probiotic bacteria during a time period in which a natural population of lactic-acid-producing indigenous intestinal bacteria is developing could theoretically in-

fluence immune development toward more balance of Th1 and Th2 inflammatory responses [89]. The intestinal bacterial flora of atopic children has been demonstrated to differ from that of nonatopic children. Specifically, atopic children have more *Clostridium* organisms and fewer *Bifidobacterium* organisms than do nonatopic study subjects [89,90]. which has served as the rationale for the administration of probiotics to infants at risk of atopic diseases, particularly for those who are formula fed. In a double-blinded RCT, LGG or a placebo was given initially to 159 women during the final 4 weeks of pregnancy. If the infant was at high risk of atopic disease (atopic eczema, allergic rhinitis, or asthma), the treatment was continued for 6 months after birth in both the lactating woman and her infant [90]. A total of 132 mother-infant pairs were randomly assigned to receive either placebo or LGG and treated for 6 months while breastfeeding. The primary study end point was chronic recurrent atopic eczema in the infant. Atopic eczema was diagnosed in 46 of 132 (35%) of these study children by 2 years of age. The frequency of atopic eczema in the LGG-treated group was 15 of 64 (23%) versus 31 of 68 (46%) in the placebo group (RR: 0.51 [95% CI: 0.32–0.84]; $P < .01$). The number of mother-infant pairs required to be treated with LGG to prevent 1 case of chronic recurrent atopic eczema was 4.5. By 4 years of age, eczema occurred in 26% of the infants in the group treated with LGG, compared with 46% in the placebo group (RR: 0.57 [95% CI: 0.33–0.97]; $P < .01$). However, only 67% of the original study group was analyzed at the 4-year follow-up. These results support a preventive effect for giving a probiotic to mothers late in pregnancy and to both mothers and infants during the first 6 months of lactation for the prevention of atopic eczema in infants who are at risk of atopic disease. However, these results have not been confirmed in subsequent clinical trials, as summarized in a recent review by Kopp and Saalfeld [91]. Conversely, found that probiotic supplementation did not reduce the risk of atopic dermatitis in children at high risk with the report of some increased risk of subsequent allergen sensitization. As concluded in a review by Prescott and Björkstén [92] and in a 2007 Cochrane review, [93] despite the encouraging results of some studies, there is insufficient evidence to warrant the routine supplementation of probiotics to either pregnant women or infants to prevent allergic diseases in childhood. Explanations for varied study results include host factors such as genetic susceptibility, environmental factors such as geographic region and diet, and study variables including probiotic strains and doses used [94,95].

Treatment of Atopic Disease

In an RCT, 53 Australian infants with moderate-to-severe atopic dermatitis were given either *Lactobacillus fermentum* or placebo for 8 weeks. At final assessment at 16 weeks, significantly more children who received the probiotic had improved extent and severity of atopic dermatitis as measured by the Severity of Scoring of Atopic Dermatitis (SCORAD) index over time compared with those who received placebo ($P = .01$) [94,95]. These results are encouraging, but as summarized in a 2008 Cochrane review [96] probiotics have not yet been proven to be effective in the treatment of eczema.

Prevention of Necrotizing Enterocolitis in Low-Birth-Weight Neonates

A new born's gut is sterile at birth, with bacterial colonization beginning shortly after birth.(97) Preterm infants frequently have delayed and aberrant acquisition of the "normal" digestive microflora, possibly because of restricted enteral feedings

and frequent use of antibiotic therapy.(98,99) Delayed enteral feeding, frequent use of antibiotic therapy, and altered acquisition of normal digestive microflora are believed to be primary contributing factors for the increased risk of necrotizing enterocolitis (NEC) in preterm infants(99) and is the rationale for probiotic supplements. In a 2008 Cochrane review based on 9 RCTs [99], enteral probiotic supplementation significantly reduced both the incidence of NEC (stage II or more) (RR: 0.32 [95% CI: 0.17–0.60]) and mortality (RR: 0.43 [95% CI: 0.25–0.75]) [100]. Nosocomial sepsis was not reduced significantly (RR: 0.93 [95% CI: 0.73–1.19]). A total of 1425 infants who were born at less than 37 weeks' gestational age and/or less than 2500 g birth weight were included in this meta-analysis. No systemic infections or serious adverse events that were directly attributed to the administered probiotic organism were reported for these RCTs. The authors concluded that the results of their analysis supported a change in clinical practice to supplement preterm infants who weighed more than 1000 g at birth with a probiotic. Data regarding the outcome of preterm extremely low birth weight infants who weighed less than 1000 g at birth could not be used by the authors to reliably estimate the efficacy and safety of probiotic supplementation to this high-risk group. A large RCT was recommended to investigate the potential benefit and safety of probiotic supplementation to extremely low birth weight infants. However, because of the large heterogeneity of the studies included in the Cochrane review [101], caution is urged in interpreting the results, which are somewhat problematic. The studies all used different probiotics, including LGG, *Bifidobacterium breve*, *Saccharomyces* species, and mixtures of *Bacteroides bifidus*, *S thermophilus*, *Lactobacillus acidophilus*, and *Bifidobacterium infantis*. Doses of individual probiotics varied and were administered with human milk feedings, formula feedings, or both human milk and formula feedings in some studies. Not all of the studies had the same end points, including the primary outcome of NEC. A second and larger study by Lin et al [102], the results of which were published after the Cochrane review, repeated the 2005 study [103] by using a different mixture of probiotics: *L acidophilus* and *B bifidus*. The overall incidence of NEC and death was less in the second study [103] compared with that in the first [104] in the controls, and the second study revealed that probiotics did not reduce the incidence of sepsis compared with that in the first, and the intervention group actually had a higher incidence of sepsis. The number needed to treat to prevent 1 case of NEC was 27 in the first study by Lin et al and 21 in the second study [105]. Another point that makes the data problematic is that the combinations of probiotics used in the Lin et al studies, which are the most convincing for NEC prevention, are not available in the United States. Not all probiotics have been studied; therefore, all probiotics cannot be generally recommended.

Infantile Colic

Prevention of Colic To date, no RCTs have been conducted with colic as a primary end point. Treatment of Colic Colic is a common condition that typically affects infants in the first 4 months of life. The primary mechanism remains unknown. Available evidence suggests that colic potentially has a number of independent causes, including dietary protein hypersensitivity [105]. A recent unblinded RCT examined the effect of the administration of *L reuteri* versus simethicone in the treatment of colic in 90 exclusively breastfed infants in Italy [106]. The administration of *L reuteri* improved the symptoms of colic (minutes of crying per day) within 1 week of treatment,

compared with simethicone therapy. The breastfeeding mothers were instructed to eliminate dairy products from their diets during the study period to minimize potentially confounding adverse effects of dietary protein hypersensitivity. The authors of the study proposed several theories for a positive therapeutic benefit, including probiotic modulation of proinflammatory responses. Further confirmatory RCTs are required to recommend routine use of probiotics in the treatment of infantile colic in both breastfed and formula-fed infants. On the basis of limited information, probiotics may be of benefit in treatment of colic in exclusively breastfed infants, but more studies are needed before they can be recommended.

Combined Prebiotics and Probiotics

To Prevent Allergy Clinical benefit in preventing allergic diseases by co-therapy

with probiotics and prebiotics in pregnant women and their infants was demonstrated in an RCT in Finland [107]. A total of 1223 pregnant women who had been identified to deliver infants who would be at high risk of atopic disease because of parental atopic disease history were randomly assigned to be given a mixture of 4 probiotic strains plus GOS or placebo daily for 2 to 4 weeks before delivery. After delivery, their infants then either received the same probiotic mixture plus GOS or the same placebo as the mother. Probiotic/prebiotic treatment showed no effect on the cumulative occurrence of allergic diseases but tended to reduce immunoglobulin E-associated (atopic) diseases (OR: 0.71 [95% CI: 0.50–1.00]; $P = .052$). Probiotic and prebiotic treatment reduced the occurrence of eczema (OR: 0.74 [95% CI: 0.55–0.98]; $P = .035$) and atopic eczema (OR: 0.66 [95% CI: 0.46–0.95]; $P = .025$). Confirmatory studies are necessary.

Prebiotics and Probiotics in Infant Formula

Prebiotics As mentioned earlier in this review, human milk contains a number of substances that are prebiotic, the most plentiful of which are oligosaccharides [107,108]. Oligosaccharide prebiotics are also added to many commercially available dietary food supplements. Regarding their addition to infant formula, the European Commission's Scientific Committee on Food concluded in 2003 that they had no major concerns regarding the addition of oligosaccharides to infant formulas, including follow-up infant formulas (formulas modified especially for 6- to 12-month-old infants), up to a total concentration of 0.8 g/dL in ready-to-feed formula products. Few RCTs have examined the effects of adding prebiotic oligosaccharides to infant formula [107,108]. Boehm et al [109], studied the effect of the addition of oligosaccharides at a concentration of 1 g/dL to preterm infant formula for 1 month (90% GOSs and 10% FOSs). Stool bifidobacteria counts in the oligosaccharide-supplemented group increased significantly compared with the nonsupplemented group, and the bifidobacteria counts reached the range of a breastfed reference group. In a separate study, Moro et al fed term infants the same oligosaccharide-supplemented formula. These infants had higher counts of bifidobacteria as well as lactobacilli in their stools. Schmelzle et al conducted a multicenter trial that also examined the efficacy of the addition of prebiotics to infant formula. They reported good overall tolerance and no adverse effects during the 12-week study period. A large multicenter trial to evaluate the safety of FOS-supplemented infant formula was conducted in the United States in 2004 [110]. The study demonstrated that infant growth was maintained during the 12-week study period for the FOS-supplemented infant-formula group without any ad-

verse effects. After weaning infants from formula, the addition of prebiotics to solid food seems to have a bifidogenic effect, as shown by the results of a recently published RCT by Scholtens et al. Infant formulas that contain either GOS or FOS are now marketed in the United States. However, more information, including data from RCTs, is needed before the efficacy of adding prebiotics to infant formulas can be determined.

Probiotics

Two infant formulas currently contain a probiotic. One contains *B lactis*, and the other contains LGG. These probiotics are only added to powdered formulas at present. The rationale for adding probiotic organisms to infant formula was discussed in the introduction of this clinical report. The overall health-benefit efficacy of adding probiotics to infant formula remains to be demonstrated in large RCTs

Osteopontin (OPN)

is a multifunctional glycoprotein found in high concentrations in human breast milk, where it plays a key role in the development of the infant's immune system, gut, and brain. Its concentration in human milk is significantly higher than in bovine milk and standard infant formulas.

Concentration in human milk

The concentration of OPN in human milk is dynamic and varies throughout lactation and based on maternal factors.

- Peak concentration: OPN levels are highest in early lactation and decrease gradually as lactation progresses. One study noted that levels can remain at about half the maximum concentration for up to 12 months.
- Maternal factors: Concentrations can be influenced by the mother's body mass index (BMI), weight gain during pregnancy, and smoking status.
- Delivery method: Some studies show that vaginal birth is associated with higher breast milk OPN levels compared to a Cesarean section, possibly linked to oxytocin expression during labor.

Functions and benefits of (OPN) for infant development

Human milk OPN resists gastric digestion, allowing it to reach the infant's intestine where it can bind to cell receptors and influence various biological processes, particularly concerning the immune system, gut health, and brain development.

Immune system development

- Balances immune response: OPN helps balance the Th1/Th2 immune response, which is skewed towards Th2 in neonates. It promotes a healthier, more balanced immune development. (114)
- Reduces inflammation: Clinical trials have shown that infants who consume OPN-fortified formula have lower levels of the pro-inflammatory cytokine TNF- α , like breastfed infants.
- Protects against infection: High levels of breast milk OPN have been correlated with a reduced number of fever-related hospitalizations during the first few months of life.
- Strengthens immune defences: Studies show OPN binds to bacteria and can enhance immune cell activity, acting as an opsonin to mark pathogens for destruction.
- Gut health and maturation
- Supports intestinal growth: Animal studies have demonstrated that dietary OPN can promote the maturation of the intestine by increasing villus height and crypt depth.

- Maintains gut barrier function: OPN helps preserve the gut barrier, reducing intestinal permeability. Studies show it can alleviate inflammation and protect against damage caused by infections or substances like alcohol.
- Influences the microbiome: Research indicates that OPN can affect the gut microbiome, influencing the populations of both beneficial and potentially harmful bacteria.
- Brain and cognitive development
- Promotes myelination: OPN plays a role in brain maturation, possibly by promoting the myelination of nerves in the central nervous system.
- Supports neurodevelopment: Its influence on brain development is thought to contribute to better cognitive function in breastfed infants compared to those on standard formula. (114,115)

Therapeutic use in infant formula

The significant difference in OPN levels between human milk and standard cow milk-based formulas has led to the development of fortified formulas.

- Bovine OPN supplement: Bovine milk OPN is now commercially available and approved for use as an ingredient in infant formula in some regions.
- Mimics human milk: Clinical studies show that supplementing formula with bovine OPN can produce immune outcomes and gene expression patterns in infants that are more like those of breastfed infants. (116,117)
- Supports vulnerable infants: For preterm infants, who have less mature gut and immune systems, OPN supplementation has shown minor improvements in gut structure and systemic immunity (118)

Safety

of Probiotics and Prebiotics in Infants and Children Concerns exist about the overall safety of administering probiotic products to high-risk patient groups, including adults, children, and term and preterm infants. Cases of serious infection have occurred and been reported in the literature. Patients at risk would be those who are immunocompromised, including ill preterm neonates, and/or children who have intravenous catheters or other indwelling medical devices. In most cases, the offending organism that caused the sepsis seems to have stemmed from bacteria from the individual's own endogenous flora. Sepsis has also been reported in adults, children, and infants who received probiotic supplements [119,120] Land et al recently reported LGG probiotic sepsis occurring in immunocompromised infants and children. A medically fragile infant 6 weeks of age became septic with a strain of LGG that was being provided as a supplement. Molecular DNA-fingerprinting confirmed that the LGG probiotic supplement was the bacterial isolate from the infant. Neonatal sepsis and meningitis that were apparently associated with the administration of a probiotic supplement were also reported. A recent report focused on probiotic tolerance and safety in healthy term infants who were randomly assigned to be given a high-dose probiotic formula, a low-dose probiotic formula, or control formula for 18 months [121]. There were no apparent reported adverse events. All infants demonstrated normal growth. Reports of colic were significantly fewer in the 2 probiotic- formula-fed groups, and the frequency of health care visits and antibiotic use was less ($P < .001$) compared with those in the control formula group. In a separate study, Pets chow et al reported that healthy term infants given varying amounts of LGG in infant formula for 2 weeks resulted in good overall feeding tolerance with successful intestinal tract colonization, without adverse events.

Summary on Safety the Committee on Nutrition of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition previously concluded that more studies are required to establish the safety and efficacy of probiotic and prebiotic products in children [121]. To date, these products seem to be safe for healthy infants and children. The committee also stated that it would be optimal to have a centralized mechanism of oversight to ensure probiotic microorganism safety, identity, and genetic stability [122]. Centralized oversight and probiotic product monitoring were also recommended in a report from the Food and Agriculture Organization of the United Nations World Health Organization. This organization supports the addition of prebiotic products to infant formulas designed as follow-up formulas meant for infants aged 5 months and older. It was reasoned that these infants are more likely to have a more mature immune response and established intestinal colonization. In terms of oversight and product safety in the United States, products marketed as dietary supplements, such as probiotics, do not require premarket review and approval by the US Food and Drug Administration (FDA). However, probiotics or prebiotics that are marketed specifically for the treatment or prevention of a disease are classified as biological products and do require FDA review and approval. Infant formulas must be made with compliance with what are considered good manufacturing practices under the Infant Formula Act of 1980 and are under the regulatory auspices of the FDA because these products are often used as the sole source of nutrition by infants during a critical period of growth and development. Additional statutory and regulatory requirements address appropriate infant formula manufacture, composition, and nutrient content. All ingredients used in infant formula must be safe and lawful—that is, food ingredients that are, to date, generally regarded as safe (GRAS) for use in infant formula and those that are used in accordance with the food-additive regulations of the FDA. Prebiotics and probiotics now being added to commercial infant formulas are classified as GRAS. Information on FDA regulations for infant formula and food ingredients and packaging may be found at www.fda.gov/Food/FoodSafety/Product-SpecificInformation/InfantFormula/default.htm and www.fda.gov/Food/FoodIngredientsPackaging/default.htm.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors would like to acknowledge the use of Biorender for the conception of the figures.

Conflicts of Interest: No conflict of interest

References

1. Macpherson AJ, Harris NL. Interactions between Commensal Intestinal Bacteria and the Immune System. *Nat. Rev. Immunol*, 2004; 4: 477–485.
2. Corthésy B. Multi-Faceted Functions of Secretory IgA at Mucosal Surfaces. *Front. Immunol*, 2013; 4: 185.
3. Arrieta MC, Stiemsma LT, Amenyogbe N, Brown E, Finlay B. The Intestinal Microbiome in Early Life: Health and Disease. *Front. Immunol*, 2014; 5: 427.
4. Korpela K. Impact of Delivery Mode on Infant Gut Microbiota. *Ann. Nutr. Metab*, 2021; 77: 11–19.
5. Ríos-Covian D, Langella P, Martín R. From Short-to Long-Term Effects of c-Section Delivery on Microbiome Establishment and Host Health. *Microorganisms*, 2021; 9: 2122.
6. Stewart CJ, Ajami NJ, O'brien JL, Hutchinson DS, Smith

- DP, Wong MC, et al. Temporal Development of the Gut Microbiome in Early Childhood from the TEDDY Study. *Nature*, 2018; 563: 583–588.
7. Bakker-Zierikzee AM, Van Tol EAF, Kroes H, Alles MS, Kok FJ, Bindels JG. Faecal SlgA Secretion in Infants Fed on Pre- or Probiotic Infant Formula. *Pediatr. Allergy Immunol*, 2006; 17: 134–140.
 8. Xiao L, Gong C, Ding Y, Ding G, Xu X, Deng C, et al. Malard, P.; Ben, X. Probiotics Maintain Intestinal Secretory Immunoglobulin A Levels in Healthy Formula-Fed Infants: A Randomised, Double-Blind, Placebo-Controlled Study. *Benef. Microbes*, 2019; 10: 729–739.
 9. Berdi M, de Lauzon-Guillain B, Forhan A, Castelli FA, Fenaile F, Charles MA, et al. Immune Components of Early Breastmilk: Association with Maternal Factors and with Reported Food Allergy in Childhood. *Pediatr. Allergy Immunol*, 2019; 30: 107–116.
 10. Adjibade M, DAVISSE-Paturet C, Divaret-Chauveau A, Adel-Patient K, Raheison C, Dufourg M-N, et al. Enrichment of Formula in Probiotics or Prebiotics and Risk of Infection and Allergic Diseases up to Age 5.5 Years in the Nationwide ELFE Cohort. *J. Nutr*, 2022; 152: 1138–1148.
 11. Food and Agriculture Organization of the United Nations; World Health Organization. Guidelines for the evaluation of probiotics in food: joint FAO/WHO Working Group report on drafting guidelines for the evaluation of probiotics in food, 2010
 12. Food and Agriculture Organization of the United Nations; World Health Organization. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria: report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria, 2010
 13. Council for Agricultural Science and Technology. Probiotics: Their Potential to Impact Human Health. Ames, IA: Council for Agricultural Science and Technology; 2007.
 14. Roberfroid M. Prebiotics: the concept revisited. *J Nutr*, 2007; 137(3 suppl 2): 830S–837S.
 15. Commane DM, Shortt CT, Silvi S, Cresci A, Hughes RM, Rowland IR. Effects of fermentation products of proand prebiotics on trans-epithelial electrical resistance in an in vitro model of the colon. *Nutr Cancer*, 2005; 51(1): 102–109.
 16. Falony G, Vlachou A, Verbrugghe K, De Vuyst L. Cross-feeding between *Bifidobacterium longum* BB536 and acetateconverting, butyrate-producing colon bacteria during growth on oligofructose. *Appl Environ Microbiol*, 2006; 72(12): 7835–7841.
 17. Grönlund MM, Gueimonde M, Laitinen K, et al. Maternal breast-milk and intestinal bifidobacteria guide the compositional development of the *Bifidobacterium* microbiota in infants at risk of allergic disease. *Clin Exp Allergy*, 2007; 37(12): 1764–1772.
 18. Heller F, Duchmann R. Intestinal flora and mucosal immune responses. *Int J Med Microbiol*, 2003; 293(1): 77–86.
 19. Berg RD. Bacterial translocation from the gastrointestinal tract. *Adv Exp Med Biol*, 1999; 473: 11–30.
 20. Quan R, Barness LA. Do infants need nucleotide supplemented formula for optimal nutrition? *J Pediatr Gastroenterol Nutr*, 1990; 11(4): 429–434
 21. Boehm G, Stahl B. Oligosaccharides from milk. *J Nutr*, 2007; 137(3 suppl 2): 847S–849S.
 22. Yoshioka H, Iseki K, Fujita K. Development and differences of intestinal flora in the neonatal period in breast-fed and bottlefed infants. *Pediatrics*, 1983; 72(3): 317–321.
 23. Weng M, Walker W. Bacterial colonization, probiotics, and clinical disease. *J Pediatr*, 2006; 149(5): S107–S114.
 24. Pietzak M. Bacterial colonization of the neonatal gut. *J Pediatr Gastroenterol Nutr*, 2004; 38(4): 389–391.
 25. Tannock G. The intestinal microflora. In: Fuller R, Perdigón G, eds. *Gut Flora, Nutrition, Immunity and Health*. Oxford, England: Blackwell Press; 2003; 1–23.
 26. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome projects. *Nature*, 2007; 449(7164): 804–810.
 27. Matsuzaki T, Takagi A, Ikemura H, Matsuguchi T, Yokokura T. Intestinal microflora: probiotics and autoimmunity. *J Nutr*, 2007; 137(3 suppl 2): 798S–802S
 28. Yuan Q, Walker WA. Innate immunity of the gut: mucosal defense in health and disease. *J Pediatr Gastroenterol Nutr*, 2004; 38(5): 463–473.
 29. Perez PF, Doré J, Leclerc M, et al. Bacterial imprinting of the neonatal immune system: lessons from maternal cells? *Pediatrics*, 2007; 119(3).
 30. Sencio V, Barthelemy A, Tavares LP, Ferreira P, Teixeira MM, Ois F, et al. Gut Dysbiosis during Influenza Contributes to Pulmonary Pneumococcal Superinfection through Altered Short-Chain Fatty Acid Production. *Cell Rep*, 2020; 30: 2934–2947.e6.
 31. Sencio V, Gallerand A, Machado G, Deruyter L. Influenza Virus Infection Impairs the Gut's Barrier Properties and Favors Secondary Enteric Bacterial Infection through Reduced Production of Short-Chain Fatty Acids. *Infect Immun*. 2021; 89: e00734-20.
 32. Food and Agriculture Organization of the United Nations; World Health Organization.
 33. Shulman RJ, Chichlowski M, Orozco FG, Harris CL, Wampler JL, Bokulich NA, et al. Infant Behavioral State and Stool Microbiome in Infants Receiving *Lactocaseibacillus Rhamnosus* GG in Formula: Randomized Controlled Trial. *BMC Pediatr*, 2022; 22: 580.
 34. Martín R, Olivares M, Marín ML, Fernández L, Xaus J, Rodríguez JM. Probiotic Potential of 3 *Lactobacilli* Strains Isolated from Breast Milk. *J. Hum. Lact*, 2005; 21: 8–17.
 35. Maldonado J, Gil-Campos M, Maldonado-Lobón JA, Benavides MR, Flores-Rojas K, Jaldo R, et al. Evaluation of the Safety, Tolerance and Efficacy of 1-Year Consumption of Infant Formula Supplemented with *Lactobacillus Fermentum* CECT5716 Lc40 or *Bifidobacterium Breve* CECT7263: A Randomized Controlled Trial. *BMC Pediatr*, 2019; 19: 361.
 36. Escribano J, Ferré N, Gispert-Llaurado M, Luque V, Rubio-Torrents C, Zaragoza-Jordana M, et al. *Bifidobacterium Longum* Subsp *Infantis* CECT7210-Supplemented Formula Reduces Diarrhea in Healthy Infants: A Randomized Controlled Trial. *Pediatr. Res*, 2018; 83: 1120–1128.
 37. Dekker J, Quilter M, Qian H. Comparison of Two Probiotics in Follow-on Formula: *Bifidobacterium Animalis* Subsp. *Lactis* HN019 Reduced Upper Respiratory Tract Infections in Chinese Infants. *Benef. Microbes*, 2022; 13: 341–353.
 38. Bazanella M, Maier TV, Clavel T, Lagkouvardos I, Lucio M, Maldonado-Gómez MX, et al. Randomized Controlled Trial on the Impact of Early-Life Intervention with *Bifidobacteria* on the Healthy Infant Fecal Microbiota and Metabolome. *Am. J. Clin. Nutr*, 2017; 106: 1274–1286.
 39. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert Consensus Document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) Consensus Statement on the Definition and Scope of Prebiotics. *Nat. Rev. Gastroenterol. Hepatol*, 2017; 14: 491–502.
 40. Bedu-Ferrari C, Biscarrat P, Langella P, Cherbuy C. Probiotics and the Human Gut Microbiota: From Breakdown Mechanisms to the Impact on Metabolic Health. *Nutrients*, 2022; 14: 2096.
 41. Sencio V, Barthelemy A, Tavares LP, Ferreira P, Teixeira MM, Ois F, et al. Gut Dysbiosis during Influenza Contributes to Pulmonary Pneumococcal Superinfection through Altered Short-Chain Fatty Acid Production. *Cell Rep*, 2020; 30: 2934–2947.e6.
 42. Sencio V, Gallerand A, Machado G, Deruyter L. Influenza Virus Infection Impairs the Gut's Barrier Properties and Favors Secondary Enteric Bacterial Infection through Reduced Production of Short-Chain Fatty Acids. *Infect Immun*, 2021; 89: e00734-20.
 43. Venter C, Meyer RW, Greenhawt M, Pali-Schöll I, Nwaru B, Roduit C, et al. Role of Dietary Fiber in Promoting Immune Health—An EAACI Position Paper. *Allergy* 2022, 77, 3185–3198.
 44. Vandenplas Y, De Greef E, Veereman G. Prebiotics in Infant Formula. *Gut Microbes*, 2014; 5: 681–687.

45. Bode L. Human Milk Oligosaccharides: Structure and Functions. In *Milk, Mucosal Immunity and the Microbiome: Impact on the Neonate*; Ogra PL, Walker WA, Lönnerdal B, Eds.; Nestlé Nutrition Institute Workshop Series; Karger: Basel, Switzerland, 2020; 94: pp. 115–123.
46. Sekerel BE, Bingol G, Cullu Cokugras F, Cokugras H, Kansu A, Ozen H, et al. An Expert Panel Statement on the Beneficial Effects of Human Milk Oligosaccharides (HMOs) in Early Life and Potential Utility of HMO-Supplemented Infant Formula in Cow's Milk Protein Allergy. *J. Asthma Allergy*, 2021; 14: 1147–1164.
47. Alliet P, Vandenplas Y, Roggero P, Jespers SNJ, Peeters S, Stalens JP, et al. Safety and Efficacy of a Probiotic-Containing Infant Formula Supplemented with 2'-Fucosyllactose: A Double-Blind Randomized Controlled Trial. *Nutr. J*, 2022; 21: 11.
48. Kong C, Faas MM, De Vos P, Akkerman R. Impact of Dietary Fibers in Infant Formulas on Gut Microbiota and the Intestinal Immune Barrier. *Food Funct*, 2020; 11: 9445–9467.
49. Goehring KC, Marriage BJ, Oliver JS, Wilder JA, Barrett EG, Buck RH. Similar to Those Who Are Breastfed, Infants Fed a Formula Containing 2'-Fucosyllactose Have Lower Inflammatory Cytokines in a Randomized Controlled Trial. *J. Nutr*, 2016; 146: 2559–2566.
50. Puccio G, Alliet P, Cajozzo C, Janssens E, Corsello G, Sprenger N, et al. Effects of Infant Formula with Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial. *J. Pediatr. Gastroenterol. Nutr*, 2017; 64: 624–631.
51. Berger B, Porta N, Foata F, Grathwohl D, Delley M, Moine D, et al. Linking Human Milk Oligosaccharides, Infant Fecal Community Types, and Later Risk to Require Antibiotics. *MBio*, 2020; 11: e03196-19.
52. Parschat K, Melsaether C, Jäpelt KR, Jennewein S. Clinical Evaluation of 16-Week Supplementation with Tolerability, Safety, and Effect on Growth. *Nutrients*, 2021; 13: 2871.
53. Lasekan J, Choe Y, Dvoretzkiy S, Devitt A, Zhang S, Mackey A, et al. Growth and Gastrointestinal Tolerance in Healthy Term Infants Fed Milk-Based Infant Formula Supplemented with Five Human Milk Oligosaccharides (HMOs): A Randomized Multicenter Trial. *Nutrients*, 2022; 14: 2625.
54. Leung TF, Ulfman LH, Chong MKC, Hon KL, Khouw IMSL, Chan PKS, et al. A Randomized Controlled Trial of Different Young Child Formulas on Upper Respiratory and Gastrointestinal Tract Infections in Chinese Toddlers. *Pediatr. Allergy Immunol*, 2020; 31: 745–754.
55. Vandenplas Y, Żoźnowska M, Berni Canani R, Ludam S, Tengelyi Z, Moreno-Alvarez A, et al. Effects of an Extensively Hydrolyzed Formula Supplemented with Two Human Milk Oligosaccharides on Growth, Tolerability, Safety and Infection Risk in Infants with Cow's Milk Protein Allergy: A Randomized, Multi-Center Trial. *Nutrients*, 2022; 14: 530.
56. Sierra C, Bernal MJ, Blasco J, Martínez R, Dalmau J, Ortuño I, et al. Prebiotic Effect during the First Year of Life in Healthy Infants Fed Formula Containing GOS as the Only Prebiotic: A Multicentre, Randomised, Double-Blind and Placebo-Controlled Trial. *Eur. J. Nutr*, 2015; 54: 89–99.
57. Giovannini M, Verduci E, Gregori D, Ballali S, Soldi S, Ghisleni D, et al. Prebiotic Effect of an Infant Formula Supplemented with Galacto-Oligosaccharides: Randomized Multicenter Trial. *J. Am. Coll. Nutr*, 2014; 33: 385–393.
58. Boženský J, Hill M, Zelenka R, Skýba T. Prebiotics Do Not Influence the Severity of Atopic Dermatitis in Infants: A Randomised Controlled Trial. *PLoS ONE*, 2015; 10: e0142897.
59. Scalabrin DMF, Mitmesser SH, Welling GW, Harris CL, Marunycz JD, Walker DC, et al. New Prebiotic Blend of Polydextrose and Galacto-Oligosaccharides Has a Bifidogenic Effect in Young Infants. *J. Pediatr. Gastroenterol. Nutr*, 2012; 54: 343–352.
60. Salminen S, Endo A, Isolauri E, Scalabrin D. Early Gut Colonization with Lactobacilli and Staphylococcus in Infants: The Hygiene Hypothesis Extended. *J. Pediatr. Gastroenterol. Nutr*, 2016; 62: 80–86.
61. Ranucci G, Buccigrossi V, Borgia E, Piacentini D, Visentin F, Cantarutti L, et al. Galacto-Oligosaccharide/Polydextrose Enriched Formula Protects against Respiratory Infections in Infants at High Risk of Atopy: A Randomized Clinical Trial. *Nutrients*, 2018; 10: 286.
62. Wernimont S, Northington R, Kullen MJ, Yao M, Bettler J. Effect of an α -Lactalbumin-Enriched Infant Formula Supplemented with Oligofructose on Fecal Microbiota, Stool Characteristics, and Hydration Status: A Randomized, Double-Blind, Controlled Trial. *Clin Pediatr*, 2015; 54: 359–370.
63. Closa-Monasterolo R, Gispert-Llaurado M, Luque V, Ferre N, Rubio-Torrents C, Zaragoza-Jordana M, et al. Safety and Efficacy of Inulin and Oligofructose Supplementation in Infant Formula: Results from a Randomized Clinical Trial. *Clin. Nutr*, 2013; 32: 918–927.
64. Neumer F, Urraca O, Alonso J, Palencia J, Varea V, Theis S, et al. Long-term Safety and Efficacy of Prebiotic Enriched Infant Formula—A Randomized Controlled Trial. *Nutrients*, 2021; 13: 1276.
65. Xia Q, Williams T, Hustead D, Price P, Morrison M, Yu Z. Quantitative Analysis of Intestinal Bacterial Populations from Term Infants Fed Formula Supplemented with Fructo-Oligosaccharides. *J. Pediatr. Gastroenterol. Nutr*, 2012; 55: 314–320.
66. Bruzzese E, Volpicelli M, Squeglia V, Bruzzese D, Salvini F, Bisceglia M, et al. A Formula Containing Galacto- and Fructo-Oligosaccharides Prevents Intestinal and Extra-Intestinal Infections: An Observational Study. *Clin. Nutr*, 2009; 28: 156–161.
67. Shahramian I, Kalvandi G, Javaherzadeh H, Khalili M, Noori NM, Delaramnasab M, et al. The Effects of Prebiotic Supplementation on Weight Gain, Diarrhoea, Constipation, Fever and Respiratory Tract Infections in the First Year of Life. *J. Paediatr. Child Health*, 2018; 54: 875–880.
68. Grüber C, Van Stuijvenberg M, Mosca F, Moro G, Chirico G, Braegger CP, et al. Immunoactive Prebiotics Transiently Prevent Occurrence of Early Atopic Dermatitis among Low-Atopy-Risk Infants. *J. Allergy Clin. Immunol*, 2015; 136: 1696–1698.e1.
69. Holscher HD, Faust KL, Czerkies LA, Litov R, Ziegler EE, Lessin H, et al. Effects of Prebiotic-Containing Infant Formula on Gastrointestinal Tolerance and Fecal Microbiota in a Randomized Controlled Trial. *J. Parenter. Enter. Nutr*, 2012; 36: 95–105.
70. Wopereis H, Sim K, Shaw A, Warner JO, Knol J, Kroll JS. Intestinal Microbiota in Infants at High Risk for Allergy: Effects of Prebiotics and Role in Eczema Development. *J. Allergy Clin. Immunol*, 2018; 141: 1334–1342.e5.
71. Boyle RJ, Tang LK, Chiang WC, Chua MC, Ismail I, Nauta A, et al. Prebiotic-Supplemented Partially Hydrolysed Cow's Milk Formula for the Prevention of Eczema in High-Risk Infants: A Randomized Controlled Trial on Behalf of the PATCH Study Investigators. *Allergy*, 2016; 71: 701–710.
72. Moro G, Arslanoglu S, Stahl B, Jelinek J, Wahn U, Boehm G. A Mixture of Prebiotic Oligosaccharides Reduces the Incidence of Atopic Dermatitis during the First Six Months of Age. *Arch Dis. Child*, 2006; 91: 814–819.
73. Van Hoffen E, Ruiter B, Faber J, M'Rabet L, Knol EF, Stahl B, et al. A Specific Mixture of Short-Chain Galacto-Oligosaccharides and Long-Chain Fructo-Oligosaccharides Induces a Beneficial Immunoglobulin Profile in Infants at High Risk for Allergy. *Allergy*, 2009; 64: 484–487.
74. Arslanoglu S, Moro GE, Schmitt J, Tandoi L, Rizzardi S, Boehm G. Early Dietary Intervention with a Mixture of Prebiotic Oligosaccharides Reduces the Incidence of Allergic Manifestations and Infections during the First Two Years of Life. *J. Nutr*, 2008; 138: 1091–1095.
75. Arslanoglu S. Early Neutral Prebiotic Oligosaccharide Supplementation Reduces the Incidence of Some Allergic Manifestations in the First 5 Years of Life. *J. Biol. Regul. Homeost. Agents*, 2012; 25: 4.
76. Zhu B, Zheng S, Lin K, Xu X, Lv L, Zhao Z, et al. Effects

- of Infant Formula Supplemented with Prebiotics and OPO on Infancy Fecal Microbiota: A Pilot Randomized Clinical Trial. *Front. Cell. Infect. Microbiol*, 2021; 11: 650407.
77. Swanson KS, Gibson GR, Hutkins R, Reimer RA, Reid G, Verbeke K, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) Consensus Statement on the Definition and Scope of Synbiotics. *Nat. Rev. Gastroenterol. Hepatol*, 2020; 17: 687–701.
 78. EFSA Panel on Dietetic Products Nutrition and Allergies Scientific Opinion on the Substantiation of Health Claims Related to Live Yoghurt Cultures and Improved Lactose Digestion (ID 1143, 2976) Pursuant to Article 13(1) of Regulation (EC) No 1924/2006. *EFSA J*, 2010; 8: 4254.
 79. Simeoni U, Berger B, Junick J, Blaut M, Pecquet S, Rezonico E, et al. Gut Microbiota Analysis Reveals a Marked Shift to Bifidobacteria by a Starter Infant Formula Containing a Synbiotic of Bovine Milk-Derived Oligosaccharides and Bifidobacterium Animalis Subsp. Lactis CNCM I-3446. *Environ. Microbiol*, 2016; 18: 2185–2195.
 80. Radke M, Picaud JC, Loui A, Cambonie G, Faas D, Lafeber HN, et al. Starter Formula Enriched in Prebiotics and Probiotics Ensures Normal Growth of Infants and Promotes Gut Health: A Randomized Clinical Trial. *Pediatr. Res*, 2017; 81; 622–631.
 81. Castanet M, Costalos C, Haiden N, Hascoet JM, Berger B, Sprenger N, et al. Early Effect of Supplemented Infant Formulae on Intestinal Biomarkers and Microbiota: A Randomized Clinical Trial. *Nutrients*, 2020; 12: 1481.
 82. Bocquet A, Lachambre E, Kempf C, Beck L. Effect of Eldeib et al ijclinmedcasereports.com Volume 28- Issue 3 12 Infant and Follow-on Formulas Containing B. Lactis and Galacto-and Fructo-Oligosaccharides on Infection in Healthy Term Infants. *J. Pediatr. Gastroenterol. Nutr*, 2013; 57: 180–187.
 83. Wong CB, Iwabuchi N, Xiao J-Z. Exploring the Science behind Bifidobacterium Breve M-16V in Infant Health. *Nutrients*, 2019; 11: 1724.
 84. Chua MC, Ben-Amor K, Lay C, Neo AGE, Chiang WC, Rao R, et al. Effect of Synbiotic on the Gut Microbiota of Cesarean Delivered Infants: A Randomized, DoubleBlind, Multicenter Study. *J. Pediatr. Gastroenterol. Nutr*, 2017; 65: 102–106.
 85. Lay C, Chu CW, Purbojati RW, Acerbi E, Drautz-Moses DI, de Sessions PF, et al. A Synbiotic Intervention Modulates Meta-Omics Signatures of Gut Redox Potential and Acidity in Elective Caesarean Born Infants. *BMC Microbiol*, 2021; 21: 191.
 86. Kosuwon P, Lao-Araya M, Uthaisangsook S, Lay C, Bindels J, Knol J, et al. A Synbiotic Mixture of ScGOS/LcFOS and Bifidobacterium Breve M-16V Increases Faecal Bifidobacterium in Healthy Young Children. *Benef. Microbes*, 2018; 9: 541–552.
 87. Van Der Aa LB, Heymans HS, Van Aalderen WM, Sillevius Smitt JH, Knol J, Ben Amor K, et al. Effect of a New Synbiotic Mixture on Atopic Dermatitis in Infants: A Randomized-Controlled Trial. *Clin. Exp. Allergy*, 2010; 40: 795–804.
 88. Van Der Aa LB, Van Aalderen WMC, Heymans HSA, Henk Sillevius Smitt J, Nauta AJ, Knippels LMJ, et al. Synbiotics Prevent Asthma-like Symptoms in Infants with Atopic Dermatitis. *Allergy* 2011, 66, 170–177.
 89. De Kivit S, Saeland E, Kraneveld AD, Van De Kant HJG, Schouten B, Van Esch BCAM, et al. Galectin-9 Induced by Dietary Synbiotics Is Involved in Suppression of Allergic Symptoms in Mice and Humans. *Allergy*, 2012; 67: 343–352.
 90. van der Aa LB, Lutter R, Heymans HAS, Smids BS, Dekker T, van Aalderen WMC, et al. No Detectable Beneficial Systemic Immunomodulatory Effects of a Specific Synbiotic Mixture in Infants with Atopic Dermatitis. *Clin. Exp. Allergy*, 2012; 42: 531–539.
 91. Sorensen K, Cawood AL, Gibson GR, Cooke LH, Stratton RJ. Amino Acid Formula Containing Synbiotics in Infants with Cow's Milk Protein Allergy: A Systematic Review and Meta-Analysis. *Nutrients*, 2021; 13: 935.
 92. Fox AT, Wopereis H, Van Ampting MTJ, Oude Nijhuis MM, Butt AM, Peroni DG, et al. A Specific Synbiotic-Containing Amino Acid-Based Formula in Dietary Management of Cow's Milk Allergy: A Randomized Controlled Trial. *Clin. Transl. Allergy*, 2019; 9: 5.
 93. Candy DCA, Van Ampting MTJ, Oude Nijhuis MM, Butt AM, Peroni DG, Vandenas Y, et al. A Synbiotic-Containing Amino-Acid-Based Formula Improves Gut Microbiota in Non-IgE-Mediated Allergic Infants. *Pediatr Res*, 2018; 83: 677–686.
 94. Wopereis H, J van Ampting MT, Cetinyurek-Yavuz A, Slump R, A Candy DC, Butt AM, et al. A Specific Synbiotic-Containing Amino Acid-Based Formula Restores Gut Microbiota in Non-IgE Mediated Cow's Milk Allergic Infants: A Randomized Controlled Trial. *Clin Transl Allergy*, 2019; 9: 1–13.
 95. Chatchatee P, Nowak-Wegrzyn A, Lange L, Benjapontitak S, Chong KW, Sangsupawanich P, et al. Tolerance Development in Cow's Milk-Allergic Infants Receiving Amino Acid-Based Formula: A Randomized Controlled Trial. *J. Allergy Clin. Immunol*, 2022; 149: 650–658.e5.
 96. Gil-Campos M, López MA, Rodriguez-Benítez MV, Romero J, Roncero I, Linares MD, et al. Lactobacillus Fermentum CECT 5716 Is Safe and Well Tolerated in Infants of 1-6 Months of Age: A Randomized Controlled Trial. *Pharmacol. Res*, 2012; 65: 231–238.
 97. Maldonado-Lobón JA, Gil-Campos M, Maldonado J, López-Huertas E, Flores-Rojas K, Valero AD, et al. Long-Term Safety of Early Consumption of Lactobacillus Fermentum CECT5716: A 3-Year Follow-up of a Randomized Controlled Trial. *Pharmacol. Res*, 2015; 95–96: 12–19.
 98. Maldonado J, Cañabate F, Sempere L, Vela F, Sánchez AR, Narbona E, et al. Human Milk Probiotic Lactobacillus Fermentum CECT5716 Reduces the Incidence of Gastrointestinal and Upper Respiratory Tract Infections in Infants. *J. Pediatr. Gastroenterol. Nutr*, 2012; 54: 55–61.
 99. Meli F, Puccio G, Cajozzo C, Ricottone GL, Pecquet S, Sprenger N, et al. Growth and Safety Evaluation of Infant Formulae Containing Oligosaccharides Derived from Bovine Milk: A Randomized, Double-Blind, Noninferiority Trial. *BMC Pediatr*, 2014; 14: 306.
 100. Szajewska H, Ruszczyński M, Szymański H, Sadowska-Krawczyńska I, Piwowarczyk A, Rasmussen PB, et al. Effects of Infant Formula Supplemented with Prebiotics Compared with Synbiotics on Growth up to the Age of 12 Mo: A Randomized Controlled Trial. *Pediatr. Res*, 2017; 81: 752–758.
 101. Rozé JC, Barbarot S, Butel MJ, Kapel N, Waligora-Dupriet AJ, De Montgolfier I, et al. An α -Lactalbumin-Enriched and Symbiotic-Supplemented v. a Standard Infant Formula: A Multicentre, Double-Blind, Randomised Trial. *Br. J. Nutr*, 2012; 107: 1616–1622.
 102. Cerdó T, Ruiz A, Acuña I, Nieto-Ruiz A, Diéguez E, Sepúlveda-Valbuena N, et al. Metabolome Dynamics in Response to an Intervention with Infant Formula Containing Specific Prebiotics and Postbiotics. *Am. J. Physiol. Gastrointest Liver Physiol*, 2022; 322: G571–G582.
 103. Roberfroid M. Prebiotics: the concept revisited. *J Nutr*, 2007; 137(3 suppl 2): 830S–837S.
 104. Commans DM, Shortt CT, Silvi S, Cresci A, Hughes RM, et al. Effects of fermentation products of proand prebiotics on trans-epithelial electrical resistance in an in vitro model of the colon. *Nutr Cancer*, 2005; 51(1): 102–109.
 105. Falony G, Vlachou A, Verbrugghe K, De Vuyst L. Cross-feeding between Bifidobacterium longum BB536 and acetateconverting, butyrate-producing colon bacteria during growth on oligofructose. *Appl Environ Microbiol*, 2006; 72(12): 7835–7841.
 106. Grönlund MM, Gueimonde M, Laitinen K, et al. Maternal breast-milk and intestinal bifidobacteria guide the compositional development of the Bifidobacterium microbiota in infants at risk of allergic disease. *Clin Exp Allergy*, 2007; 37(12): 1764–1772.
 107. Heller F, Duchmann R. Intestinal flora and mucosal immune responses. *Int J Med Microbiol*, 2003; 293(1): 77–86.
 108. Berg RD. Bacterial translocation from the gastrointestinal tract. *Adv Exp Med Biol*, 1999; 473: 11–30.
 109. Quan R, Barness LA. Do infants need nucleotide supple-

- mented formula for optimal nutrition? *J Pediatr Gastroenterol Nutr*, 1990; 11(4): 429 – 434
110. Boehm G, Stahl B. Oligosaccharides from milk. *J Nutr*, 2007; 137(3 suppl 2): 847S– 849S.
111. Bocquet A, Lachambre E, Kempf C, Beck L. Effect of Eldeib et al ijclinmedcasereports.com Volume 28- Issue 3 12 Infant and Follow-on Formulas Containing B. Lactis and Galacto-and Fructo-Oligosaccharides on Infection in Healthy Term Infants. *J. Pediatr. Gastroenterol. Nutr*, 2013; 57: 180–187.
112. Wong CB, Iwabuchi N, Xiao J-Z. Exploring the Science behind Bifidobacterium Breve M-16V in Infant Health. *Nutrients*, 2019; 11: 1724.
113. Chua MC, Ben-Amor K, Lay C, Neo AGE, Chiang WC, Rao R, et al. Effect of Synbiotic on the Gut Microbiota of Cesarean Delivered Infants: A Randomized, DoubleBlind, Multicenter Study. *J. Pediatr. Gastroenterol. Nutr*, 2017; 65: 102–106.
114. Lay C, Chu CW, Purbojati RW, Acerbi E, Drautz-Moses DI, de Sessions PF, et al. A Synbiotic Intervention Modulates Meta-Omics Signatures of Gut Redox Potential and Acidity in Elective Caesarean Born Infants. *BMC Microbiol*, 2021; 21: 191.
115. Kosuwon P, Lao-Araya M, Uthaisangsook S, Lay C, Bindels J, Knol J, et al. A Synbiotic Mixture of ScGOS/LcFOS and Bifidobacterium Breve M-16V Increases Faecal Bifidobacterium in Healthy Young Children. *Benef. Microbes*, 2018; 9: 541–552.
116. Van Der Aa LB, Heymans HS, Van Aalderen WM, Sillevius Smitt JH, Knol J, Ben Amor K, et al. Effect of a New Synbiotic Mixture on Atopic Dermatitis in Infants: A Randomized-Controlled Trial. *Clin. Exp. Allergy*, 2010; 40: 795–804.
117. Sodek J, Ganss B, McKee MD. Osteopontin. *Crit. Rev. Oral Biol. Med.* 2000; 11: 279–303. doi: 10.1177/10454411000110030101.
118. Icer MA, Gezmen-Karadag M. The Multiple Functions and Mechanisms of Osteopontin. *Clin. Biochem*, 2018; 59: 17–24. doi: 10.1016/j.clinbiochem.2018.07.003.
119. Lok ZSY, Lyle AN. Osteopontin in Vascular Disease. *Arterioscler. Thromb. Vasc. Biol*, 2019; 39: 613–622. doi: 10.1161/ATVBAHA.118.311577.
120. Senger DR, Perruzzi CA, Papadopoulos A, Tenen DG. Purification of a Human Milk Protein Closely Similar to Tumor-Secreted Phosphoproteins and Osteopontin. *Biochim. Biophys. Acta BBA-Protein Struct. Mol. Enzymol*, 1989; 996: 43–48. doi: 10.1016/0167-4838(89)90092-7.
121. Sørensen ES, Petersen TE. Purification and Characterization of Three Proteins Isolated from the Proteose Peptone Fraction of Bovine Milk. *J. Dairy Res*, 1993; 60: 189–197. doi: 10.1017/S0022029900027503.
122. Plaza-Diaz J, Ruiz-Ojeda FJ, Morales J, de la Torre AIC, García-García A, de Prado CN, et al. Effects of a Novel Infant Formula on Weight Gain, Body Composition, Safety and Tolerability to Infants: The INNOVA 2020 Study. *Nutrients*, 2023; 15: 147.